Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
216 studies found for:    "essential thrombocythemia"
Show Display Options
Rank Status Study
21 Completed
Has Results
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Condition: Essential Thrombocythaemia
Intervention: Drug: Anagrelide hydrochloride
22 Recruiting Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Conditions: Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
Intervention:
23 Completed Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: CYT387
24 Completed Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
25 Not yet recruiting 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia
Conditions: Essential Thrombocythemia;   Primary Myelofibrosis, Fibrotic Stage;   Primary Myelofibrosis, Prefibrotic Stage
Intervention: Device: Diagnostic (18F-FLT PET/CT)
26 Active, not recruiting Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: NS-018
27 Completed
Has Results
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Conditions: Primary Myelofibrosis (PMF);   Post Polycythaemia Myelofibrosis (PPV MF);   Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Intervention: Drug: INC424
28 Recruiting Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Conditions: Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
Intervention: Drug: Ruxolitinib (INCB018424)
29 Completed Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Momelotinib
30 Active, not recruiting Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Conditions: Idiopathic Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis;   Post Polycythemia-Vera Myelofibrosis
Interventions: Drug: panobinostat;   Drug: ruxolitinib
31 Active, not recruiting Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Conditions: Primary Myelofibrosis (PMF);   Post-polycythemia Vera (Post-PV);   Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions: Drug: Momelotinib;   Drug: Best Available Therapy (BAT)
32 Enrolling by invitation Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis;   Polycythemia Vera;   Essential Thrombocythemia
Intervention: Drug: Momelotinib
33 Recruiting Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Conditions: Polycythemia Vera;   Essential Thrombocythemia
Intervention: Procedure: Blood specimen
34 Completed Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Conditions: Polycythemia Vera;   Essential Thrombocytosis
Intervention: Drug: lestaurtinib
35 No longer available INC424 for Patients With Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis
Conditions: Myelofibrosis (PMF);   Post Polycythemia Myelofibrosis (PPV MF);   Post-essential Thrombocythemia Myelofibrosis (PET-MF);   Myelofibrosis;   Post Polycythemia Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Intervention: Drug: INC424
36 Completed
Has Results
A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Condition: Primary Myelofibrosis (MF)
Intervention: Drug: Ruxolitinib
37 Completed
Has Results
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Conditions: Primary Myelofibrosis (PMF);   Post-Polycythaemia Vera;   Essential Thrombocythaemia Myelofibrosis
Intervention: Drug: AZD1480
38 Active, not recruiting An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Fibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: itacitinib
39 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
40 Terminated Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
Interventions: Drug: Pacritinib;   Drug: Best Available Therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.